Ombitasvir/Paritaprevir/Ritonavir & Dasabuvir (DSC)

DEA Class; Rx

Common Brand Names; Viekira Pak (DSC)

  • HCV NS5A Inhibitors; 
  • HCV Polymerase Inhibitors; 
  • HCV Protease Inhibitors

Combination oral product containing 3 antivirals with activity against HCV and a pharmacokinetic enhancer
For HCV genotype 1a and 1b, including patients with and without compensated cirrhosis
Contraindicated in patients with moderate to severe hepatic disease (Child-Pugh Class B and C)

Indicated for the treatment of chronic hepatitis C infection.

Adults

500 mg/day PO for dasabuvir; 25 mg/day PO for ombitasvir; 150 mg/day PO for paritaprevir; 100 mg/day PO for ritonavir.

Geriatric

500 mg/day PO for dasabuvir; 25 mg/day PO for ombitasvir; 150 mg/day PO for paritaprevir; 100 mg/day PO for ritonavir.

Adolescents

Safety and efficacy not established.

Children

Safety and efficacy not established.

Infants

Safety and efficacy not established.

Neonates

Safety and efficacy not established.

ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) (Discontinued)

Fixed-dose combination discontinued in 2015 owing to hepatoxicity

About the Author

You may also like these

0